CEO Joseph Burnett stated that ClearPoint Neuro ended 2025 on its strongest financial quarter of the year, highlighting "a newly acquired and commercialized neurocritical care product line and genuine ...

ClearPoint Neuro reported Q3 2025 revenue of $8.9M, up 9% YoY, with gross margin improving to 63%. Management reaffirmed 2025 revenue guidance of $36–38M and introduced 2026 pro forma guidance of ...

ClearPoint Neuro's progress on its four-pillar strategy continues despite a challenging operating environment, with an increasing number of partners and hospital sites featuring its equipment. The ...

ClearPoint Neuro delivered Q2 2026 revenue of $10.9M, up 18% YoY, with notable segment variability: strong neurosurgery navigation and capital equipment growth offset a 15% decline in biologics and ...

ClearPoint Neuro CLPT recently unveiled the development of its proprietary Robotic Neuro-Navigation System, a move that positions the company to contribute to robotics, neurosurgery, and advanced drug ...